Genomma Lab Internacional, S.A.B. de C.V. GNMLF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 97.36M | 90.83M | 87.49M | 83.76M | 57.43M |
| Total Depreciation and Amortization | 20.75M | 20.66M | 20.18M | 19.77M | 20.63M |
| Total Amortization of Deferred Charges | 1.03M | 1.03M | 1.03M | 1.03M | 596.60K |
| Total Other Non-Cash Items | 68.30M | 54.67M | 49.10M | 42.98M | 70.80M |
| Change in Net Operating Assets | -81.09M | -65.92M | -52.45M | -36.55M | -43.07M |
| Cash from Operations | 106.34M | 101.27M | 105.35M | 111.00M | 106.38M |
| Capital Expenditure | -27.19M | -32.77M | -30.29M | -28.93M | -25.00M |
| Sale of Property, Plant, and Equipment | 2.09M | 3.47M | 636.70K | 580.00K | 619.40K |
| Cash Acquisitions | -11.77M | -11.12M | -8.11M | -7.88M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.49M | 8.43M | -1.56M | -4.00M | 3.46M |
| Cash from Investing | -24.38M | -32.00M | -39.34M | -40.23M | -20.92M |
| Total Debt Issued | 4.85B | 3.60B | 5.37B | 5.03B | 5.13B |
| Total Debt Repaid | -4.27B | -3.07B | -4.25B | -3.89B | -4.37B |
| Issuance of Common Stock | 1.83B | 1.83B | 1.86B | 1.86B | 1.71B |
| Repurchase of Common Stock | -1.88B | -1.89B | -1.88B | -1.91B | -1.75B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -44.29M | -54.01M | -42.79M | -41.24M | -39.69M |
| Other Financing Activities | -657.84M | -717.72M | -737.73M | -781.34M | -853.42M |
| Cash from Financing | -52.47M | -68.66M | -22.73M | -26.21M | -46.54M |
| Foreign Exchange rate Adjustments | -3.76M | -7.17M | -15.25M | -13.49M | -8.86M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.73M | -6.55M | 28.03M | 31.07M | 30.06M |